Associated Papers
BRAF in non-small cell lung cancer: From molecular mechanisms to clinical practice.
Parisi C et al.
Cancer, 2025
Cancer and disease profiles for PTEN pathogenic variants in Japanese population.
Kanazashi Y et al.
Journal of Human Genetics, 2025
39663357 (PubMed )
Supplement: 10038_2024_1311_MOESM1_ESM.xlsx › Table_S9
BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape.
Planchard D et al.
Npj Precision Oncology, 2024
Source, co-occurrence, and prognostic value of PTEN mutations or loss in colorectal cancer.
Serebriiskii IG et al.
Npj Genomic Medicine, 2023
38001126 (PubMed )
Supplement: 41525_2023_384_MOESM1_ESM.xlsx › Table_S6
Simultaneous Nbs1 and p53 inactivation in neural progenitors triggers high-grade gliomas.
Reuss DE et al.
Neuropathology and Applied Neurobiology, 2023
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer.
Ortiz-Cuaran S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
Squamous cell transformation as a mechanism of acquired resistance to tyrosine kinase inhibitor in EGFR-mutated lung adenocarcinoma: a report of two cases.
Uruga H et al.
Respirology Case Reports, 2020
A functional dissection of PTEN N-terminus: implications in PTEN subcellular targeting and tumor suppressor activity.
Gil A et al.
Plos One, 2015
Select a paper to view details